bolt biotherapeutics is a start-up with compelling technology from dr. engleman’s lab at stanford university, which demonstrated complete cures in numerous cancer models. the company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.
Company profile
Ticker
BOLT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Bolt Therapeutics, Inc.
SEC CIK
Corporate docs
IRS number
472804636
BOLT stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
Latest ownership filings
4
Grant Yonehiro
6 Mar 24
4
Edith A. Perez
6 Mar 24
4
Randall C Schatzman
6 Mar 24
4
William P. Quinn
6 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Vivo Capital VIII, LLC
13 Feb 24
SC 13D/A
Pivotal bioVenture Partners Fund I, L.P.
12 Feb 24
5
Grant Yonehiro
6 Feb 24
5
Edith A. Perez
6 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.93 mm | 10.93 mm | 10.93 mm | 10.93 mm | 10.93 mm | 10.93 mm |
Cash burn (monthly) | 1.36 mm | 104.75 k | 6.06 mm | 6.46 mm | 5.58 mm | 6.10 mm |
Cash used (since last report) | 9.08 mm | 697.56 k | 40.36 mm | 42.99 mm | 37.18 mm | 40.63 mm |
Cash remaining | 1.84 mm | 10.23 mm | -29.44 mm | -32.07 mm | -26.25 mm | -29.70 mm |
Runway (months of cash) | 1.4 | 97.6 | -4.9 | -5.0 | -4.7 | -4.9 |
Institutional ownership, Q2 2023
93.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 7 |
Closed positions | 6 |
Increased positions | 7 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 31.33 bn |
Total shares | 35.72 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vivo Capital | 3.87 mm | $4.96 bn |
Tang Capital Management | 3.33 mm | $4.27 bn |
Pivotal bioVenture Partners Fund I | 3.06 mm | $0.00 |
Citadel Advisors | 2.99 mm | $3.82 bn |
Sofinnova Investments | 2.75 mm | $3.53 bn |
Sofinnova Venture Partners X | 2.75 mm | $0.00 |
Tang Capital Partners | 2.73 mm | $3.72 mm |
Vivo Capital VIII | 2.27 mm | $77.06 mm |
Pivotal bioVenture Partners Investment Advisor | 1.89 mm | $2.42 bn |
Orbimed Advisors | 1.54 mm | $1.97 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Mar 24 | Grant Yonehiro | Stock Option Common Stock | Grant | Acquire A | No | No | 1.27 | 235,000 | 298.45 k | 235,000 |
4 Mar 24 | Edith A. Perez | Stock Option Common Stock | Grant | Acquire A | No | No | 1.27 | 235,000 | 298.45 k | 235,000 |
4 Mar 24 | Randall C Schatzman | Stock Option Common Stock | Grant | Acquire A | No | No | 1.27 | 654,000 | 830.58 k | 235,000 |
4 Mar 24 | Quinn William P. | Stock Option Common Stock | Grant | Acquire A | No | No | 1.27 | 235,000 | 298.45 k | 235,000 |
6 Dec 23 | Grant Yonehiro | Common Stock | Buy | Acquire P | No | No | 0.782 | 2,500 | 1.96 k | 8,918 |